Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia

C. Zhang, KYY. Chan, WH. Ng, JTK. Cheung, Q. Sun, H. Wang, PY. Chung, FWT. Cheng, AWK. Leung, XB. Zhang, PY. Lee, SP. Fok, G. Lin, ENY. Poon, JH. Feng, YL. Tang, XQ. Luo, LB. Huang, W. Kang, PMK. Tang, J. Huang, C. Chen, J. Dong, E. Mejstrikova,...

. 2024 ; 109 (9) : 2833-2845. [pub] 20240901

Language English Country Italy

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24019198

Resistance to glucocorticoids (GC), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting the mechanisms shaping GC resistance could lead to new treatment modalities. Here, we showed that CD9- BCP-ALL cells were preferentially resistant to prednisone and dexamethasone over other standard cytotoxic agents. Concordantly, we identified significantly more poor responders to the prednisone prephase among BCP-ALL patients with a CD9- phenotype, especially for those with adverse presenting features including older age, higher white cell count and BCR-ABL1. Furthermore, gain- and loss-offunction experiments dictated a definitive functional linkage between CD9 expression and GC susceptibility, as demonstrated by the reversal and acquisition of relative GC resistance in CD9low and CD9high BCP-ALL cells, respectively. Despite physical binding to the GC receptor NR3C1, CD9 did not alter its expression, phosphorylation or nuclear translocation but potentiated the induction of GC-responsive genes in GC-resistant cells. Importantly, the MEK inhibitor trametinib exhibited higher synergy with GC against CD9- than CD9+ lymphoblasts to reverse drug resistance in vitro and in vivo. Collectively, our results elucidate a previously unrecognized regulatory function of CD9 in GC sensitivity, and inform new strategies for management of children with resistant BCP-ALL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019198
003      
CZ-PrNML
005      
20241024111648.0
007      
ta
008      
241015s2024 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2023.282952 $2 doi
035    __
$a (PubMed)38572553
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Zhang, Chi $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
245    10
$a CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia / $c C. Zhang, KYY. Chan, WH. Ng, JTK. Cheung, Q. Sun, H. Wang, PY. Chung, FWT. Cheng, AWK. Leung, XB. Zhang, PY. Lee, SP. Fok, G. Lin, ENY. Poon, JH. Feng, YL. Tang, XQ. Luo, LB. Huang, W. Kang, PMK. Tang, J. Huang, C. Chen, J. Dong, E. Mejstrikova, J. Cai, Y. Liu, S. Shen, JJ. Yang, PMP. Yuen, CK. Li, KT. Leung
520    9_
$a Resistance to glucocorticoids (GC), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting the mechanisms shaping GC resistance could lead to new treatment modalities. Here, we showed that CD9- BCP-ALL cells were preferentially resistant to prednisone and dexamethasone over other standard cytotoxic agents. Concordantly, we identified significantly more poor responders to the prednisone prephase among BCP-ALL patients with a CD9- phenotype, especially for those with adverse presenting features including older age, higher white cell count and BCR-ABL1. Furthermore, gain- and loss-offunction experiments dictated a definitive functional linkage between CD9 expression and GC susceptibility, as demonstrated by the reversal and acquisition of relative GC resistance in CD9low and CD9high BCP-ALL cells, respectively. Despite physical binding to the GC receptor NR3C1, CD9 did not alter its expression, phosphorylation or nuclear translocation but potentiated the induction of GC-responsive genes in GC-resistant cells. Importantly, the MEK inhibitor trametinib exhibited higher synergy with GC against CD9- than CD9+ lymphoblasts to reverse drug resistance in vitro and in vivo. Collectively, our results elucidate a previously unrecognized regulatory function of CD9 in GC sensitivity, and inform new strategies for management of children with resistant BCP-ALL.
650    _2
$a lidé $7 D006801
650    12
$a pre-B-buněčná leukemie $x farmakoterapie $x metabolismus $x genetika $x patologie $7 D015452
650    12
$a antigeny CD9 $x metabolismus $x genetika $7 D060245
650    12
$a glukokortikoidy $x farmakologie $x terapeutické užití $7 D005938
650    12
$a chemorezistence $x genetika $7 D019008
650    _2
$a dítě $7 D002648
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a receptory glukokortikoidů $x metabolismus $x genetika $7 D011965
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dexamethason $x farmakologie $7 D003907
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chan, Kathy Yuen Yee $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Ng, Wing Hei $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Cheung, John Tak Kit $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Sun, Qiwei $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Wang, Han $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Chung, Po Yee $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Cheng, Frankie Wai Tsoi $u Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Kowloon Bay
700    1_
$a Leung, Alex Wing Kwan $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Zhang, Xiao-Bing $u Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Tianjin
700    1_
$a Lee, Po Yi $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Fok, Siu Ping $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Lin, Guanglan $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Poon, Ellen Ngar Yun $u School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin
700    1_
$a Feng, Jian-Hua $u Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
700    1_
$a Tang, Yan-Lai $u Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
700    1_
$a Luo, Xue-Qun $u Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
700    1_
$a Huang, Li-Bin $u Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
700    1_
$a Kang, Wei $u Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin
700    1_
$a Tang, Patrick Ming Kuen $u Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin
700    1_
$a Huang, Junbin $u Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen
700    1_
$a Chen, Chun $u Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen
700    1_
$a Dong, Junchao $u Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou
700    1_
$a Mejstrikova, Ester $u CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Cai, Jiaoyang $u Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai
700    1_
$a Liu, Yu $u Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai
700    1_
$a Shen, Shuhong $u Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai
700    1_
$a Yang, Jun J $u Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
700    1_
$a Yuen, Patrick Man Pan $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin
700    1_
$a Li, Chi Kong $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong; Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Shatin
700    1_
$a Leung, Kam Tong $u Department of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong; Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Shatin. ktleung@cuhk.edu.hk
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 109, č. 9 (2024), s. 2833-2845
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38572553 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111642 $b ABA008
999    __
$a ok $b bmc $g 2201814 $s 1231171
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 109 $c 9 $d 2833-2845 $e 20240901 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options